Washington State University to review claims of research misconduct
06/18/2021 - 01:09 PM
PULLMAN, Wash. , June 18, 2021 /PRNewswire/ -- Washington State University announced today that it has undertaken a review of claims of potential research misconduct involving research conducted by Leen Kawas , a former WSU student and current president and chief executive officer of Athira Pharma, Inc. (NASDAQ: ATHA). On Thursday, the Athira Pharma board of directors announced that it had placed Kawas on temporary leave pending its own review of actions stemming from Kawas' doctoral research while at WSU.
Washington State University expects its researchers to adhere to the highest ethical standards in the conduct of research activities. The University takes allegations of research misconduct very seriously. WSU is conducting its inquiry into this issue in accordance with the University's Executive Policy 33 , which governs how the institution responds to allegations of research misconduct.
Washington State University will refrain from discussing the matter further until the review process is complete.
http://www.prnewswire.com/news-releases/washington-state-university-to-review-claims-of-research-misconduct-301315597.html
SOURCE Washington State University
ATHA Rankings
#4750 Ranked by Stock Gains
ATHA Stock Data
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
Tags
Commercial Services, Miscellaneous Commercial Services, Health Technology, Biotechnology, Manufacturing, Medicinal and Botanical Manufacturing
About ATHA
m3 biotechnology is an innovative therapeutics company that has a novel platform of disease-modifying regenerative small molecules, particularly relevant to neurodegenerative diseases. the lead compound modifies growth-factor systems, where the activation is expected to stop disease progression and even restore lost function. the company’s research has been funded by the alzheimer’s drug discovery foundation, washington’s life sciences discovery fund, w fund, wrf capital, dolby family ventures and other private investors. where current and emerging therapies are focused primarily on disease symptoms and improving the quality of life of patients suffering from disease, m3 differentiates itself from the competition by addressing the neurodegenerative process, providing a cost-effective solution and feasible delivery mechanism. our strategy is to leverage our patented and proprietary technologies to develop small molecule modulators with a primary focus on altering the course of alzheimer
